Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch

Set Alert for Stockwatch

Stockwatch: The Mixed History Of Biotech Company Separations

The path of spin-offs from loss-making biotech companies with weak investment propositions seems clouded with examples that often resulted in an appointment with the liquidator.

Stockwatch Deals

Stockwatch: Subdued Virtual J.P. Morgan Conference Prefaces Full-Year Earnings Season

Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.

Stockwatch M & A

Stockwatch: New Year, New Politics; Same Old Pricing And Generic Challenges

A positive start to the year for healthcare stocks was accompanied, as usual, by drug price increases. This and the other issues that have been carried over from 2020 remain just as challenging.

Pricing Debate Sales & Earnings

Stockwatch: When Cash May Not Be King

Agios’s divestment of its oncology pipeline and commercial operations provided a rare case where all parties appeared satisfied. In many other cases, there are winners and losers.

M & A Deals

Stockwatch: Big Pharma Buys Bargain-Basement Big Biotech

The acquisitions of Alexion and Celgene are the latest in a long line of transactions in which big pharma buys big biotech. But these latest two are of biotechs that have disappointed their investors, and there are still some of those left for 2021.

M & A Strategy

Stockwatch: Politics And Profits May Pollute Pharma’s Pandemic Response

It is hard enough speeding novel vaccines against novel pathogens to global markets whilst balancing profit imperatives with societal benefit. Political interventions have the potential to introduce additional friction.

Strategy Stockwatch
See All
UsernamePublicRestriction

Register